Pharnext Aktie

Pharnext SA develops and manufactures drugs for neurological diseases. Its products include R&D Pipeline, PXT3003, and PXT864 are used for the treatment of Charcot-Marie-Tooth disease, diabetic, and toxic peripheral neuropathies, as well as severe neurodegenerative diseases in general and peripheral neuropathies. The company was founded in 2007 by Daniel Cohen, Loic Heidsieck, Serguei Nabirotchkine, Oxana Guerassimenko and Ilya Chumakov and is headquartered in Paris, France.